We bring over a decade of experience working with leading pharmaceutical, biotech, and academic partners to advance immuno-oncology and immunotherapy research. Our scientists, trained in top pharma environments, combine deep expertise with advanced platforms to uncover immune–tumor interactions, evaluate therapeutic responses, and identify predictive biomarkers. With a proven track record of collaboration and innovation, we deliver reliable insights that help accelerate the development of next-generation immunotherapies.
We provide a comprehensive range of custom immunoassay services, including assay development, validation, clinical trial testing, and CLIA-certified testing. With deep expertise in antibody and antigen development, our team streamlines workflows to reduce development time and ensure reliable, high-quality results.
Our services cover every stage of the process—from meeting regulatory requirements and sourcing analytes, antibodies, and control samples, to optimizing dilution factors, incubation times, and assay conditions. We establish robust acceptance criteria, conduct sensitivity and precision analyses, and define detection limits with accuracy. By combining technical rigor with regulatory insight, we deliver assays tailored to meet the highest scientific and clinical standards.
We specialize in converting traditional ELISA assays into advanced formats such as Luminex, Lumit, AlphaLISA, DELFIA, or HTRF, streamlining workflows and eliminating time-consuming, costly steps.
Have questions? Ask Axela — we’re here to help.
📧 info@axelabio.com